Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors
Preprint
- 17 January 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Immune checkpoint inhibitors have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in the real-world practice. Methods We conducted a retrospective study on patients with recurrent or metastatic non-small cell lung cancer, melanoma, renal cell carcinoma, or gastric cancer who received anti-PD-1/PD-L1 antibodies (nivolumab, pembrolizumab, or atezolizumab) at the Keio University Hospital between September 2014 and January 2019. We recorded treatment-related AEs from medical records and graded them using the Common Terminology Criteria for Adverse Events version 4. We performed an overall survival (OS) analysis using a Cox proportional hazards model. Results Among 212 patients eligible for this study, 108 experienced irAEs and 42 developed multiple irAEs. OS in patients with multiple irAEs was significantly longer than that in patients with single irAE (42.3 months vs. 18.8 months; hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.25–0.93; P = 0.03). Moreover, OS from the development of a second irAE in those with multiple irAEs was longer than that from the development of the first irAE in patients with single irAEs (median OS, 26.9 months vs. 17.7 months, respectively; HR, 0.59; 95% CI, 0.30–1.14; P = 0.11). Conclusions Our single-center retrospective study revealed a remarkable tendency associating the development of multiple irAEs with favorable prognoses.Keywords
This publication has 29 references indexed in Scilit:
- Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapyEuropean Journal of Cancer, 2019
- Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patientsEuropean Journal of Cancer, 2019
- Biomarkers of response to immune checkpoint blockade in cancer treatmentCritical Reviews in Oncology/Hematology, 2018
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumabLung Cancer, 2018
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceInvestigational New Drugs, 2017
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialThe Lancet Oncology, 2016
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With PembrolizumabJAMA Dermatology, 2016
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015